Patents by Inventor Lloyd B. Klickstein

Lloyd B. Klickstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240002843
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: October 13, 2022
    Publication date: January 4, 2024
    Applicants: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF
    Publication number: 20220265823
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Shinji HATAKEYAMA, Ronenn ROUBENOFF, Estelle TRIFILIEFF, Jerome FEIGE, Lloyd B. KLICKSTEIN
  • Uses of myostatin antagonists, combinations containing them and uses thereof
    Patent number: 11357851
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilieff, Jerome Feige, Lloyd B. Klickstein
  • USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF
    Publication number: 20200254090
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Application
    Filed: November 9, 2016
    Publication date: August 13, 2020
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilirff, Jerome Feige, Lloyd B Klickstein
  • DOSAGE REGIMEN FOR THE TREATMENT OF ENDOMETRIOSIS
    Publication number: 20190192485
    Abstract: This invention relates to a dosage regimen comprising 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive for use in the treatment of endometriosis in a non-pregnant, pre-menopausal female. The invention also relates to a multi-phase combination preparation comprising 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive. The invention also relates to a kit comprising said multi-phase preparation and instructions for use.
    Type: Application
    Filed: August 21, 2017
    Publication date: June 27, 2019
    Applicant: MEREO BIOPHARMA 2 LIMITED
    Inventors: Jackie PARKIN, Lloyd B. KLICKSTEIN
  • AZABICYCLOOCTANE DERIVATIVES AS FXR AGONISTS FOR USE IN THE TREATMENT OF LIVER AND GASTROINTESTINAL DISEASES
    Publication number: 20190083473
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 21, 2019
    Inventors: Michael Badman, Lloyd B. Klickstein, Bryan Laffitte
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190010495
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 26, 2016
    Publication date: January 10, 2019
    Applicants: NOVARTIS AG, INTELLIA THERAPEUTICS, INC.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • Pharmaceutical compositions comprising an aromatse inhibitors
    Patent number: 10064844
    Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 4, 2018
    Assignee: MEREO BIOPHARMA 2 LIMITED
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES
    Publication number: 20180066067
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 8, 2018
    Applicant: NOVARTIS AG
    Inventors: Feng CONG, Huaixiang HAO, Lloyd B. KLICKSTEIN, Rou-Fun KWONG, Ann TAYLOR, Yang XIE
  • MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA
    Publication number: 20170260275
    Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.
    Type: Application
    Filed: December 4, 2015
    Publication date: September 14, 2017
    Inventors: Patrick KORTEBEIN, Daniel ROOKS, Lloyd B. KLICKSTEIN, Ronenn ROUBENOFF, David GLASS, Estelle TRIFILIEFF, Dimitris PAPANICOLAOU
  • Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
    Patent number: 9750724
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AN AROMATSE INHIBITORS
    Publication number: 20160346257
    Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicant: MEREO BIOPHARMA 2 LIMITED
    Inventors: Ann TAYLOR, Lloyd B. KLICKSTEIN, Jeewan THAKUR
  • USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES
    Publication number: 20160243084
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 25, 2016
    Applicant: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • Pharmaceutical compositions comprising an aromatse inhibitors
    Patent number: 9370505
    Abstract: The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: June 21, 2016
    Assignee: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
    Patent number: 9295668
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: March 29, 2016
    Assignee: Merco BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • Antibodies and methods for WNT pathway-related diseases
    Patent number: 9296826
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: March 29, 2016
    Assignee: NOVARTIS AG
    Inventors: Feng Cong, Huaixiang Hao, Lloyd B. Klickstein, Rou-Fun Kwong, Ann Taylor, Yang Xie
  • ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES
    Publication number: 20140328859
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Feng Cong, Huaixiang Hao, Lloyd B. Klickstein, Rou-Fun Kwong, Ann Taylor, Yang Xie
  • USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES
    Publication number: 20140309267
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Application
    Filed: September 6, 2012
    Publication date: October 16, 2014
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AN AROMATSE INHIBITORS
    Publication number: 20140213622
    Abstract: The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents.
    Type: Application
    Filed: September 6, 2012
    Publication date: July 31, 2014
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • Molecules and Methods for Modulating Complement Component
    Publication number: 20090175875
    Abstract: Compositions that bind to C3b epitopes and methods of using the compositions are described herein.
    Type: Application
    Filed: November 3, 2008
    Publication date: July 9, 2009
    Inventors: Bijan ETEMAD-GILBERTSON, Braydon Charles Guild, Mark Taylor Keating, Yong-In Kim, Lloyd B. Klickstein, Dmitri Mikhailov, Mariusz Milik, Michael Roguska, Igor Splawski, Kehao Zhao